| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon.
|
N Engl J Med
|
2008
|
9.33
|
|
2
|
Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection.
|
N Engl J Med
|
2014
|
9.25
|
|
3
|
A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.
|
N Engl J Med
|
2006
|
7.35
|
|
4
|
Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.
|
N Engl J Med
|
2006
|
5.65
|
|
5
|
Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma.
|
Gastroenterology
|
2009
|
4.50
|
|
6
|
Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment.
|
Gastroenterology
|
2004
|
4.27
|
|
7
|
Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort.
|
Hepatology
|
2005
|
3.95
|
|
8
|
Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C.
|
Hepatology
|
2009
|
3.50
|
|
9
|
Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders.
|
Control Clin Trials
|
2004
|
3.46
|
|
10
|
Detection of hepatocellular carcinoma at advanced stages among patients in the HALT-C trial: where did surveillance fail?
|
Am J Gastroenterol
|
2013
|
3.41
|
|
11
|
Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma.
|
J Hepatol
|
2005
|
3.18
|
|
12
|
NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States.
|
Hepatology
|
2002
|
2.96
|
|
13
|
GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma.
|
J Hepatol
|
2005
|
2.70
|
|
14
|
Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis.
|
Cancer Epidemiol Biomarkers Prev
|
2012
|
2.57
|
|
15
|
Hospital readmissions among patients with decompensated cirrhosis.
|
Am J Gastroenterol
|
2011
|
2.49
|
|
16
|
Outcomes of living donor liver transplantation for acute liver failure: the adult-to-adult living donor liver transplantation cohort study.
|
Liver Transpl
|
2008
|
2.30
|
|
17
|
Hepatitis B therapy.
|
Nat Rev Gastroenterol Hepatol
|
2011
|
2.23
|
|
18
|
Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B.
|
Gastroenterology
|
2007
|
2.11
|
|
19
|
Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients.
|
Hepatology
|
2003
|
2.05
|
|
20
|
CD73 (ecto-5'-nucleotidase) hepatocyte levels differ across mouse strains and contribute to mallory-denk body formation.
|
Hepatology
|
2013
|
2.04
|
|
21
|
One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study.
|
Am J Gastroenterol
|
2005
|
2.04
|
|
22
|
Modified Charlson comorbidity index for predicting survival after liver transplantation.
|
Liver Transpl
|
2007
|
1.96
|
|
23
|
Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg?
|
Hepatology
|
2015
|
1.87
|
|
24
|
Weight-related effects on disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial.
|
Gastroenterology
|
2009
|
1.80
|
|
25
|
Liver transplantation for erythropoietic protoporphyria liver disease.
|
Liver Transpl
|
2005
|
1.76
|
|
26
|
Energy determinants GAPDH and NDPK act as genetic modifiers for hepatocyte inclusion formation.
|
J Cell Biol
|
2011
|
1.72
|
|
27
|
Risk factors for hepatocellular carcinoma may impair the performance of biomarkers: a comparison of AFP, DCP, and AFP-L3.
|
Cancer Biomark
|
2007
|
1.65
|
|
28
|
Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence.
|
Liver Transpl
|
2007
|
1.61
|
|
29
|
Renal outcomes after liver transplantation in the model for end-stage liver disease era.
|
Liver Transpl
|
2009
|
1.49
|
|
30
|
Improving the prediction of hepatocellular carcinoma in cirrhotic patients with an arterially-enhancing liver mass.
|
Liver Transpl
|
2005
|
1.47
|
|
31
|
Liver transplantation outcomes among Caucasians, Asian Americans, and African Americans with hepatitis B.
|
Liver Transpl
|
2009
|
1.46
|
|
32
|
Burden of cirrhosis on older Americans and their families: analysis of the health and retirement study.
|
Hepatology
|
2012
|
1.44
|
|
33
|
Machine learning algorithms outperform conventional regression models in predicting development of hepatocellular carcinoma.
|
Am J Gastroenterol
|
2013
|
1.39
|
|
34
|
A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C.
|
Hepatology
|
2011
|
1.33
|
|
35
|
An intention-to-treat analysis of liver transplantation for hepatocellular carcinoma using organ procurement transplant network data.
|
Liver Transpl
|
2009
|
1.31
|
|
36
|
Sensitivity and accuracy of an updated line probe assay (HBV DR v.3) in detecting mutations associated with hepatitis B antiviral resistance.
|
J Hepatol
|
2008
|
1.25
|
|
37
|
A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation.
|
Hepatology
|
2013
|
1.21
|
|
38
|
Frequency of elevated hepatocellular carcinoma (HCC) biomarkers in patients with advanced hepatitis C.
|
Am J Gastroenterol
|
2011
|
1.20
|
|
39
|
SRM targeted proteomics in search for biomarkers of HCV-induced progression of fibrosis to cirrhosis in HALT-C patients.
|
Proteomics
|
2012
|
1.11
|
|
40
|
An IL28B genotype-based clinical prediction model for treatment of chronic hepatitis C.
|
PLoS One
|
2011
|
1.04
|
|
41
|
Effect of HCV RNA suppression during peginterferon alfa-2a maintenance therapy on clinical outcomes in the HALT-C trial.
|
Gastroenterology
|
2009
|
1.03
|
|
42
|
Cognitive function in hepatitis C patients with advanced fibrosis enrolled in the HALT-C trial.
|
J Hepatol
|
2005
|
0.98
|
|
43
|
Does antiviral therapy prevent hepatocellular carcinoma?
|
Antivir Ther
|
2011
|
0.92
|
|
44
|
Impaired virion secretion by hepatitis B virus immune escape mutants and its rescue by wild-type envelope proteins or a second-site mutation.
|
J Virol
|
2012
|
0.90
|
|
45
|
Mallory-Denk bodies are associated with outcomes and histologic features in patients with chronic hepatitis C.
|
Clin Gastroenterol Hepatol
|
2011
|
0.90
|
|
46
|
Monitoring antiviral resistance in patients receiving nucleos(t)ide analog therapies for hepatitis B: which method should be used?
|
J Hepatol
|
2008
|
0.89
|
|
47
|
Hepatitis B screening and vaccination practices in asian american primary care.
|
Gut Liver
|
2013
|
0.89
|
|
48
|
Clinical relevance of cognitive scores in hepatitis C patients with advanced fibrosis.
|
J Clin Exp Neuropsychol
|
2006
|
0.88
|
|
49
|
CDC and USPSTF 2012 recommendations for screening for hepatitis C virus infection: overview and take-home messages.
|
Clin Gastroenterol Hepatol
|
2013
|
0.88
|
|
50
|
Who decides? Living donor liver transplantation for advanced hepatocellular carcinoma.
|
Transplantation
|
2006
|
0.86
|
|
51
|
Hepatitis B prevalence among Asian Americans in Michigan: an assessment to guide future education and intervention strategies.
|
J Community Health
|
2010
|
0.83
|
|
52
|
Histologic outcomes in hepatitis C-infected patients with varying degrees of virologic response to interferon-based treatments.
|
Hepatology
|
2010
|
0.82
|
|
53
|
Impact of the hepatitis B virus genotype on pre- and post-liver transplantation outcomes.
|
Liver Transpl
|
2008
|
0.81
|
|
54
|
Predicting cirrhosis and clinical outcomes in patients with advanced chronic hepatitis C with a panel of genetic markers (CRS7).
|
Pharmacogenet Genomics
|
2011
|
0.80
|
|
55
|
Interferon-free treatment regimens for hepatitis C: are we there yet?
|
Gastroenterology
|
2011
|
0.80
|
|
56
|
New approaches to optimize treatment responses in chronic hepatitis B.
|
Antivir Ther
|
2010
|
0.80
|
|
57
|
YKL-40 genetic polymorphisms and the risk of liver disease progression in patients with advanced fibrosis due to chronic hepatitis C.
|
Liver Int
|
2011
|
0.79
|
|
58
|
No increase in depression with low-dose maintenance peginterferon in prior non-responders with chronic hepatitis C.
|
J Affect Disord
|
2011
|
0.78
|
|
59
|
Reduction in Hepatic Inflammation Is Associated With Less Fibrosis Progression and Fewer Clinical Outcomes in Advanced Hepatitis C.
|
Am J Gastroenterol
|
2012
|
0.78
|
|
60
|
A comparative study of patients' attitudes toward clinical research in the United States and urban and rural China.
|
Clin Transl Sci
|
2015
|
0.78
|
|
61
|
CDC and USPSTF 2012 recommendations for screening for hepatitis C virus infection: overview and take-home messages.
|
Gastroenterology
|
2013
|
0.77
|
|
62
|
Should liver biopsies be performed on all hepatitis B carriers?
|
Gastroenterology
|
2008
|
0.75
|
|
63
|
Do guidelines preclude hepatitis B patients from receiving treatment?
|
Hepatology
|
2009
|
0.75
|
|
64
|
Should treatment of hepatitis B patients be based solely on liver fibrosis?
|
Clin Gastroenterol Hepatol
|
2013
|
0.75
|
|
65
|
What is the optimal regimen for preventing hepatitis B recurrence after liver transplantation?
|
Nat Clin Pract Gastroenterol Hepatol
|
2008
|
0.75
|
|
66
|
Reply to Giannini and Trevisani.
|
Am J Gastroenterol
|
2013
|
0.75
|
|
67
|
Should antiviral treatment be extended to patients with chronic hepatitis B and mildly elevated alanine aminotransferase?
|
Hepatology
|
2010
|
0.75
|
|
68
|
A comparative study of patients' knowledge about hepatitis C in the United States and in urban and rural China.
|
Hepatol Int
|
2014
|
0.75
|
|
69
|
Population-Based Analysis and Projections of Liver Supply Under Redistricting.
|
Transplantation
|
2017
|
0.75
|
|
70
|
Authorship: who should be included and how should it be determined?
|
Gastroenterology
|
2011
|
0.75
|